Health
Cancer Prevention
2015 IPO

Interpace Diagnostics

$0.8101
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0298 (-3.55%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell IDXG and other stocks, options, ETFs, and crypto commission-free!

About

Interpace Diagnostics Group, Inc. operates as an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. Read More The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.

Employees
89
Headquarters
Parsippany, New Jersey
Founded
1986
Market Cap
24.10M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
403.71K
High Today
$0.8499
Low Today
$0.8001
Open Price
$0.8411
Volume
186.72K
52 Week High
$1.78
52 Week Low
$0.7561

Collections

Health
Cancer Prevention
2015 IPO
US
North America

News

MarketBeatMar 8

Stock Price, News, & Analysis for Interpace Diagnostics Group

News stories about IDXG stock have been trending somewhat positive on Saturday, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Interpace Diagnostics Group earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned press coverage about t...

150
Simply Wall StFeb 28

Those Who Purchased Interpace Diagnostics Group Shares Five Years Ago Have A 98% Loss To Show For It

Long term investing works well, but it doesn’t always work for each individual stock. We don’t wish catastrophic capital loss on anyone. Spare a thought for those who held Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) for five whole years – as the share price tanked 98%. There was little comfort for shareholders in the last week as the price declined a further 2.9%. We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don’t have to lose the les...

471

Earnings

-$0.11
-$0.10
-$0.08
-$0.07
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.08 per share
Actual
-$0.09 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.